COMMUNIQUÉS West-GlobeNewswire

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
30/03/2026
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose [...]
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
30/03/2026
Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned [...]
Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
30/03/2026
Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of lomitapide to include [...]
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
30/03/2026
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, [...]
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
30/03/2026
Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a [...]
Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
30/03/2026
PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, [...]
Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis
30/03/2026
Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE NEWSWIRE) -- Levicept [...]
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
30/03/2026
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package highlights well-tolerated [...]
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
30/03/2026
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
30/03/2026
COPENHAGEN, Denmark, March 30, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Arch Biopartners Arranges Non-Brokered Private Placement
30/03/2026
TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 1,000,000 [...]
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
30/03/2026
U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) Ongoing [...]
Camila Japur joins Tecan as Chief Financial Officer
30/03/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Camila Japur joins Tecan as Chief Financial Officer Männedorf, Switzerland, March 30, 2026 – The Tecan Group (SIX Swiss Exchange: [...]
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
30/03/2026
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children [...]
Draupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical Biology
30/03/2026
Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets Study further details platform [...]
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
30/03/2026
The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test delivers faster turnaround times and [...]
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
30/03/2026
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late- [...]
NANOBIOTIX annonce la présentation des premières données de l’étude de phase 2 randomisée évaluant JNJ-1900 (NBTXR3) dans le cancer du poumon inopérable de stade III
30/03/2026
Données présentées par Johnson & Johnson lors de la conférence annuelle européenne 2026 sur le cancer du poumon (ELCC) PARIS et CAMBRIDGE, Mass., 30 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ [...]
Medical AI Named First-Ever Recipient of ACC Global Digital Health Award at American College of Cardiology Annual Scientific Session
29/03/2026
AI platform recognized for real-world clinical impact through analysis of raw 12-lead ECG data, enabling earlier detection of multiple cardiovascular diseases NEW ORLEANS, March 29, 2026 (GLOBE NEWSWIRE) -- Medical AI, [...]

Pages